A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number one in prescription market...